Iris Unito Prodmetadata only
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial
cure model, dostarlimab, dostarlimab plus chemotherapy, mixture cure model, dmmr/msi-h ec
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 308481
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.